fbpx Skip to main content

Member's Profile


23 Corporate Plaza Drive, Suite 150
United States
Membership Info
Membership Type: Industry
Membership Since: 2021
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About jCyte
Biotech Company
jCyte, Inc. is a research and development company that has developed a cell-based therapy, jCell, designed to preserve and restore vision in people with retinitis pigmentosa and potentially other blinding diseases. jCell is a first-in-class investigational treatment in late-stage clinical development for retinitis pigmentosa (RP). The treatment is a minimally-invasive intravitreal injection, which can be performed in an ophthalmologist’s office with topical anesthetic. The principal mechanism of action is the sustained release of established neurotrophic factors that reduce photoreceptor cell death and promote function of surviving photoreceptors. jCell therapy aims to preserve vision by intervening in the disease at a time when host photoreceptors can be protected and potentially reactivated. There are currently no FDA approved treatment options for the vast majority of patients with retinitis pigmentosa. Unlike gene therapy approaches, jCell does not target any specific genotype.
Related News
No related news posted by this Member